What dosage does Wegovy go up to, and how does the titration schedule work?

The decision you're probably facing: is it safe to keep going higher?

If you're already on Wegovy and wondering how far the doses actually go, you're not alone. A lot of people reach 1.0 mg or 1.7 mg and genuinely aren't sure whether there's more road ahead, or whether the ceiling is closer than they thought. That uncertainty is worth addressing clearly, because the answer has changed in the last twelve months.

Wegovy's original licensed schedule runs to 2.4 mg per week, which was the standard maintenance dose when the medicine was first approved in the UK. That dose remains the most commonly prescribed endpoint for the majority of patients. If you've been reading about a higher option, that's now also approved: the MHRA confirmed a 7.2 mg weekly dose in early 2026, and a dedicated single-dose pen to deliver it was approved on 14 April 2026, making this a genuinely new frontier for semaglutide prescribing in the UK. You can read the official announcement on GOV.UK's news page covering the 7.2 mg Wegovy pen approval.

What the dose ladder looks like end to end, and which level makes clinical sense for you, depends on things your prescriber needs to weigh up. The sections below lay out the facts so you can have that conversation with confidence. For a broader overview of the treatment itself, the Wegovy treatment guide on this site covers mechanism, eligibility and what to expect day to day.

The standard Wegovy dose schedule: five rungs, roughly one month each

Semaglutide in Wegovy is introduced at 0.25 mg per week. This starting dose isn't intended to produce significant weight loss, its job is to let your digestive system get used to the medicine. Nausea, the most commonly reported side effect, is far more manageable when the dose climbs slowly.

From there the schedule moves up approximately every four weeks: 0.25 mg, then 0.5 mg, 1.0 mg, 1.7 mg and finally 2.4 mg. That's roughly five months to reach the maintenance dose if every step goes smoothly, which for many people it does. For a closer look at what each rung involves, the Wegovy dosage page walks through the schedule in more detail.

At 2.4 mg, clinical trial data from the STEP 1 study (published in the New England Journal of Medicine) showed an average body-weight reduction of around 15% over 68 weeks. That figure is a trial average, not a forecast for any individual, and your prescriber will review your response to the maintenance dose before making any further decision. The NHS medicines page for semaglutide also covers what to expect during titration.

One practical point: if a dose increase causes significant side effects, your prescriber may hold the current dose for an extra four weeks rather than pushing ahead. Pausing a rung is not a failure; it's the intended safety mechanism.

The 7.2 mg dose: what's new, who it's for, and what the evidence shows

If you're curious about what dose Wegovy goes up to, the highest it now reaches is 7.2 mg per week. This isn't a separate medicine, it's semaglutide at a higher concentration, approved by the MHRA following trial evidence that more weight reduction is achievable at this level for some patients.

The approved 7.2 mg single-dose pen uses an auto-dosing mechanism with a built-in covered needle that locks after use. It is licensed for adults with a BMI of 30 or above. Importantly, the 7.2 mg dose is not approved under the separate cardiovascular-risk indication for Wegovy, so it applies specifically to weight management in people who meet that BMI threshold. Specific dose and pen availability is confirmed at consultation, availability is confirmed at consultation rather than guaranteed in advance.

Trial data around the 7.2 mg dose reported average weight loss of around 20.7% over 72 weeks, which brings semaglutide noticeably closer to the results seen with tirzepatide at its highest doses. That narrowing of the gap matters clinically; if you've been researching both medicines, the weight-loss treatment overview is a useful starting point for comparison. For a full picture of how high Wegovy dosage goes, the titration pathway to 7.2 mg still begins at 0.25 mg (the starting dose does not change) and the prescriber manages each step up in the same four-weekly pattern.

What this means if you're considering Wegovy, or already on it

The dose you'll reach depends on your individual response and your prescriber's clinical judgement. Some people do well at 1.7 mg and stay there. Others climb to 2.4 mg and maintain that level for the full treatment period. The 7.2 mg option adds a further path for those whose prescriber decides it's appropriate, but it's not a default progression, it's a decision made case by case.

There are a few things worth knowing as you think this through. Wegovy is a prescription-only medicine; the dose schedule described here is the licensed framework, not a self-managed plan. Missed doses, whether to slow down a titration, and any switch to a higher dose pen are all conversations for your prescriber and the Wegovy SmPC on the eMC. The Patient Information Leaflet that comes with each pen is the authoritative source for storage, missed-dose guidance and injection technique.

On the question of what treatment costs at different dose levels, the Wegovy pricing page explains how private costs vary by strength and what a legitimate price should include. For anyone approaching this from the beginning (working out whether Wegovy suits their situation at all) the question of which dose actually drives weight loss is a natural next step.

If you'd like a prescriber to review your situation and advise on the right starting point or next dose, check your eligibility through a free consultation with the clinical team at nume.